Insightec’s Exablate Neuro provides an incisionless treatment option for essential tremour and tremour-dominant Parkinson’s disease patients. Credit: Marvin 101.

Israel-based medical technology company Insightec has signed a definitive agreement for funding of about $150m to support continued research to evaluate focused ultrasound for the treatment of certain movement disorders.

Series F financing at a post-money valuation of $1.3bn is led by Koch Industries’ subsidiary Koch Disruptive Technologies (KDT), which has committed to invest $100m at an initial closing to follow shareholder approval.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This is the second direct investment by the company in Insightec.

In 2016, Insightec obtained the US Food and Drug Administration (FDA) approval for its Exablate Neuro system for the treatment of certain movement disorders in patients with essential tremor and tremor-dominant Parkinson’s disease.

Exablate incisionless neurosurgery platform is the first MR-guided ultrasound device.

Insightec CEO and Board chairman Maurice Ferré said: “Our partnership with KDT and other investors is helping to fuel our momentum as a rapidly growing number of medical institutions adopt our focused ultrasound technology. This new investment demonstrates our investors’ commitment to help drive the next generation of focused ultrasound.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Exablate Neuro system is said to facilitate an immediate tremor improvement after the outpatient procedure. It promises minimal risk of infection, bleeding or other surgical complications.

Koch Disruptive Technologies president Chase Koch said: “Insightec’s focused ultrasound technology is disrupting the way surgery has been performed for generations. KDT is focused on empowering innovative companies and helping them realise their potential to improve the lives of millions of people.”

Insightec states that around 65 medical centres across the world have adopted the system to treat patients with essential tremor.